Ganswindt U - Search Results

1

SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy.

De-Colle C, Menegakis A, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Abu Jawad J, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Belka C, Ganswindt U, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D; DKTK-ROG. De-Colle C, et al. Among authors: ganswindt u. Radiother Oncol. 2018 Jan;126(1):125-131. doi: 10.1016/j.radonc.2017.10.008. Epub 2017 Oct 20. Radiother Oncol. 2018. PMID: 29061496

2

70 Gy or more: which dose for which prostate cancer?

Ganswindt U, Paulsen F, Anastasiadis AG, Stenzl A, Bamberg M, Belka C. Ganswindt U, et al. J Cancer Res Clin Oncol. 2005 Jul;131(7):407-19. doi: 10.1007/s00432-005-0681-0. Epub 2005 May 11. J Cancer Res Clin Oncol. 2005. PMID: 15887028 Review.

3

Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study.

Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Ganswindt U, et al. Radiat Oncol. 2006 Apr 10;1:9. doi: 10.1186/1748-717X-1-9. Radiat Oncol. 2006. PMID: 16722607 Free PMC article. Clinical Trial.

4

Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study.

Hehr T, Classen J, Welz S, Ganswindt U, Scheithauer H, Koitschev A, Bamberg M, Budach W. Hehr T, et al. Among authors: ganswindt u. Radiother Oncol. 2006 Jul;80(1):33-8. doi: 10.1016/j.radonc.2006.05.016. Epub 2006 Jul 27. Radiother Oncol. 2006. PMID: 16875750 Clinical Trial.

5

[Recurrence of prostate cancer--value of salvage radiotherapy].

Belka C, Ganswindt U. Belka C, et al. Among authors: ganswindt u. Urologe A. 2006 Oct;45(10):1266-70. doi: 10.1007/s00120-006-1210-8. Urologe A. 2006. PMID: 17006699 Review. German.

6

Optimized coverage of high-risk adjuvant lymph node areas in prostate cancer using a sentinel node-based, intensity-modulated radiation therapy technique.

Ganswindt U, Paulsen F, Corvin S, Hundt I, Alber M, Frey B, Stenzl A, Bares R, Bamberg M, Belka C. Ganswindt U, et al. Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):347-55. doi: 10.1016/j.ijrobp.2006.08.082. Int J Radiat Oncol Biol Phys. 2007. PMID: 17236960

7

Risk of second malignancies after prostate irradiation?

Müller AC, Ganswindt U, Bamberg M, Belka C. Müller AC, et al. Among authors: ganswindt u. Strahlenther Onkol. 2007 Nov;183(11):605-9. doi: 10.1007/s00066-007-1786-y. Strahlenther Onkol. 2007. PMID: 17960335 Review.

8

Analysis of complex protein kinase B signalling pathways in human prostate cancer samples.

Jendrossek V, Henkel M, Hennenlotter J, Vogel U, Ganswindt U, Müller I, Handrick R, Anastasiadis AG, Kuczyk M, Stenzl A, Belka C. Jendrossek V, et al. Among authors: ganswindt u. BJU Int. 2008 Aug;102(3):371-82. doi: 10.1111/j.1464-410X.2008.07703.x. Epub 2008 May 12. BJU Int. 2008. PMID: 18476967

9

Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard?

Ganswindt U, Stenzl A, Bamberg M, Belka C. Ganswindt U, et al. Eur Urol. 2008 Sep;54(3):528-42. doi: 10.1016/j.eururo.2008.06.059. Epub 2008 Jun 23. Eur Urol. 2008. PMID: 18602742 Review.

10

[Radiotherapy in prostate cancer].

Ganswindt U, Belka C. Ganswindt U, et al. Urologe A. 2008 Sep;47(9):1245-54; quiz 1255. doi: 10.1007/s00120-008-1846-7. Urologe A. 2008. PMID: 18641965 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

182 results

Search Page

Filters